Latest Viropharma Inc (VPHM) Headlines ViroPhar
Post# of 1
Posted On: 03/13/2014 3:35:51 PM
Latest Viropharma Inc (VPHM) Headlines
ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017
M2 - Tue Feb 25, 8:49AM CST
ViroPharma Incorporated today announced the results
ViroPharma Announces Results of Tender Offer for its 2.00% Convertible Senior Notes Due 2017
PR Newswire - Tue Feb 25, 6:10AM CST
ViroPharma Incorporated today announced the results of its tender offer (the "Convertible Notes Tender Offer") pursuant to which each holder of the 2.00% Convertible Senior Notes Due 2017 (the "Convertible Notes") had the right (the "Fundamental Change Repurchase Right") to require ViroPharma to repurchase all of such holder's Convertible Notes, or any portion thereof that is a multiple of $1,000 principal amount, on February 25, 2014. The Fundamental Change Repurchase Right expired at 5:00 p.m., New York City time, on February 24, 2014 (the "Fundamental Change Expiration Time"), and was not extended. ViroPharma has been advised by Wilmington Trust Company, the Paying Agent and the Conversion Agent for the Convertible Notes Tender Offer, that none of the Notes were validly surrendered for repurchase prior to the Fundamental Change Expiration Time.
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/42bsgj/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome). Scope - A snapshot of the global therapeutic scenario for Neuromyelitis Optica (Devic's Syndrome). - A review of the Neuromyelitis Optica (Devic's Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuromyelitis Optica (Devic's Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Neuromyelitis Optica (Devic's Syndrome) Overview Therapeutics Development Clinical Stage Products Early Stage Products Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment Drug Profiles eculizumab - Drug Profile NPB-01 - Drug Profile NU-211-01 NU-215-02 - Drug Profile conestat alfa - Drug Profile HL-161 - Drug Profile ALN-CC5 - Drug Profile Neuromyelitis Optica (Devic's Syndrome) - Recent Pipeline Updates Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones Featured News & Press Releases Appendix Methodology Companies Mentioned ViroPharma Incorporated Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. HanAll Biopharma Co., Ltd. Shenzhen Beike Biotechnology Co., Ltd. Nihon Pharmaceutical Industry Co., Ltd. For more information visit http://www.researchandmarkets.com/research/42...romyelitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Did Billionaire Mario Gabelli's Company Buy Diebold, Responsys, and ViroPharma?
Selena Maranjian, The Motley Fool - Motley Fool - Fri Feb 14, 4:15PM CST
The latest 13F season is commencing, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and...
Joint Statement From Treasury Secretary And GDB Chairman Regarding Fitch Ratings Action
PR Newswire - Tue Feb 11, 9:43AM CST
Today, Treasury Secretary Melba Acosta Febo and Government Development Bank for Puerto Rico (GDB) Chairman David H. Chafey commented on Fitch Ratings' decision regarding outstanding bonds of the Commonwealth and related entities.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uptrend Call Working As Viropharma Stock Rises 43.2% (VPHM)
Comtex SmarTrend(R) - Fri Jan 31, 9:49AM CST
SmarTrend identified an Uptrend for Viropharma (NASDAQ:VPHM) on September 13th, 2013 at $34.89. In approximately 5 months, Viropharma has returned 43.21% as of today's recent price of $49.96.
Juniper, Synaptics Stocks Bolt Up Despite Downturn
at Investor's Business Daily - Tue Jan 28, 7:02AM CST
Major indices were down again Monday after falling last week on concerns over emerging markets, but Synaptics (SYNA), Juniper Networks (JNPR), GasLog (GLOG) and McKesson (MCK) are all holding or moving higher during the downturn. All four companies...
Why 2014 Could Be a Huge Year for M&A Activity
Peter Stephens, The Motley Fool - Motley Fool - Sun Jan 26, 3:15PM CST
Mergers and acquisitions -- M&A -- are a key part of the health-care sector, with companies routinely buying other companies, as well as entering into joint ventures and collaborating on the development of specific drugs. Indeed, 2014 has...
Nasdaq stocks posting largest volume decreases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
ViroPharma Announces Tender Offer for its 2.00% Convertible Senior Notes Due 2017
PR Newswire - Fri Jan 24, 2:16PM CST
ViroPharma, Inc. today announced that, in connection with the completion of the acquisition of ViroPharma by Shire plc (LSE: SHP, NASDAQ: SHPG), it has commenced a tender offer (the "Convertible Notes Tender Offer") to repurchase, at the option of each holder, any and all of its outstanding 2.00% Convertible Senior Notes Due 2017 (the "Convertible Notes"). Earlier in the day on January 24, 2014, Shire completed the tender offer for all of the outstanding shares of common stock of ViroPharma, consummated the merger of ViroPharma into Venus Newco, Inc., a wholly owned subsidiary of Shire, and terminated trading of ViroPharma's common stock on NASDAQ, and the directors of ViroPharma immediately prior to the effective time of the merger were replaced with the directors of Venus Newco, Inc., each of which constituted a Fundamental Change (as defined in the indenture governing the Convertible Notes (the "Indenture") triggering ViroPharma's obligation to commence the Convertible Notes Tender Offer.
Viropharma Shares Up 43.2% Since SmarTrend's Buy Recommendation (VPHM)
Comtex SmarTrend(R) - Fri Jan 24, 9:24AM CST
SmarTrend identified an Uptrend for Viropharma (NASDAQ:VPHM) on September 13th, 2013 at $34.89. In approximately 4 months, Viropharma has returned 43.21% as of today's recent price of $49.96.
Shire successfully completes tender offer for ViroPharma
M2 - Fri Jan 24, 9:08AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014), and was not extended.
Shire Successfully Completes Tender Offer for ViroPharma
PR Newswire - Fri Jan 24, 6:51AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014), and was not extended.
Shire Sells Dermagraft - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:55PM CST
Shire entered into a definitive agreement with Organogenesis Inc. to sell Dermagraft.
Shire Quickly Pulls Off Dermagraft
at The Street - Fri Jan 17, 8:37AM CST
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.
Tractor Supply Set to Join the S&P 500; Align Technology to Join MidCap 400; Roadrunner Transportation and Boise Cascade to Join S&P SmallCap 600
PR Newswire - Thu Jan 16, 4:50PM CST
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective after the close of trading on Thursday, January 23:
Small-Cap Growth Stocks: A Long-Term Winning Investment
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jan 16, 4:15PM CST
Follow @SelenaMaranjian // full story)
ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017
M2 - Tue Feb 25, 8:49AM CST
ViroPharma Incorporated today announced the results
ViroPharma Announces Results of Tender Offer for its 2.00% Convertible Senior Notes Due 2017
PR Newswire - Tue Feb 25, 6:10AM CST
ViroPharma Incorporated today announced the results of its tender offer (the "Convertible Notes Tender Offer") pursuant to which each holder of the 2.00% Convertible Senior Notes Due 2017 (the "Convertible Notes") had the right (the "Fundamental Change Repurchase Right") to require ViroPharma to repurchase all of such holder's Convertible Notes, or any portion thereof that is a multiple of $1,000 principal amount, on February 25, 2014. The Fundamental Change Repurchase Right expired at 5:00 p.m., New York City time, on February 24, 2014 (the "Fundamental Change Expiration Time"), and was not extended. ViroPharma has been advised by Wilmington Trust Company, the Paying Agent and the Conversion Agent for the Convertible Notes Tender Offer, that none of the Notes were validly surrendered for repurchase prior to the Fundamental Change Expiration Time.
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/42bsgj/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome). Scope - A snapshot of the global therapeutic scenario for Neuromyelitis Optica (Devic's Syndrome). - A review of the Neuromyelitis Optica (Devic's Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuromyelitis Optica (Devic's Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Neuromyelitis Optica (Devic's Syndrome) Overview Therapeutics Development Clinical Stage Products Early Stage Products Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment Drug Profiles eculizumab - Drug Profile NPB-01 - Drug Profile NU-211-01 NU-215-02 - Drug Profile conestat alfa - Drug Profile HL-161 - Drug Profile ALN-CC5 - Drug Profile Neuromyelitis Optica (Devic's Syndrome) - Recent Pipeline Updates Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones Featured News & Press Releases Appendix Methodology Companies Mentioned ViroPharma Incorporated Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. HanAll Biopharma Co., Ltd. Shenzhen Beike Biotechnology Co., Ltd. Nihon Pharmaceutical Industry Co., Ltd. For more information visit http://www.researchandmarkets.com/research/42...romyelitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Did Billionaire Mario Gabelli's Company Buy Diebold, Responsys, and ViroPharma?
Selena Maranjian, The Motley Fool - Motley Fool - Fri Feb 14, 4:15PM CST
The latest 13F season is commencing, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and...
Joint Statement From Treasury Secretary And GDB Chairman Regarding Fitch Ratings Action
PR Newswire - Tue Feb 11, 9:43AM CST
Today, Treasury Secretary Melba Acosta Febo and Government Development Bank for Puerto Rico (GDB) Chairman David H. Chafey commented on Fitch Ratings' decision regarding outstanding bonds of the Commonwealth and related entities.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uptrend Call Working As Viropharma Stock Rises 43.2% (VPHM)
Comtex SmarTrend(R) - Fri Jan 31, 9:49AM CST
SmarTrend identified an Uptrend for Viropharma (NASDAQ:VPHM) on September 13th, 2013 at $34.89. In approximately 5 months, Viropharma has returned 43.21% as of today's recent price of $49.96.
Juniper, Synaptics Stocks Bolt Up Despite Downturn
at Investor's Business Daily - Tue Jan 28, 7:02AM CST
Major indices were down again Monday after falling last week on concerns over emerging markets, but Synaptics (SYNA), Juniper Networks (JNPR), GasLog (GLOG) and McKesson (MCK) are all holding or moving higher during the downturn. All four companies...
Why 2014 Could Be a Huge Year for M&A Activity
Peter Stephens, The Motley Fool - Motley Fool - Sun Jan 26, 3:15PM CST
Mergers and acquisitions -- M&A -- are a key part of the health-care sector, with companies routinely buying other companies, as well as entering into joint ventures and collaborating on the development of specific drugs. Indeed, 2014 has...
Nasdaq stocks posting largest volume decreases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
ViroPharma Announces Tender Offer for its 2.00% Convertible Senior Notes Due 2017
PR Newswire - Fri Jan 24, 2:16PM CST
ViroPharma, Inc. today announced that, in connection with the completion of the acquisition of ViroPharma by Shire plc (LSE: SHP, NASDAQ: SHPG), it has commenced a tender offer (the "Convertible Notes Tender Offer") to repurchase, at the option of each holder, any and all of its outstanding 2.00% Convertible Senior Notes Due 2017 (the "Convertible Notes"). Earlier in the day on January 24, 2014, Shire completed the tender offer for all of the outstanding shares of common stock of ViroPharma, consummated the merger of ViroPharma into Venus Newco, Inc., a wholly owned subsidiary of Shire, and terminated trading of ViroPharma's common stock on NASDAQ, and the directors of ViroPharma immediately prior to the effective time of the merger were replaced with the directors of Venus Newco, Inc., each of which constituted a Fundamental Change (as defined in the indenture governing the Convertible Notes (the "Indenture") triggering ViroPharma's obligation to commence the Convertible Notes Tender Offer.
Viropharma Shares Up 43.2% Since SmarTrend's Buy Recommendation (VPHM)
Comtex SmarTrend(R) - Fri Jan 24, 9:24AM CST
SmarTrend identified an Uptrend for Viropharma (NASDAQ:VPHM) on September 13th, 2013 at $34.89. In approximately 4 months, Viropharma has returned 43.21% as of today's recent price of $49.96.
Shire successfully completes tender offer for ViroPharma
M2 - Fri Jan 24, 9:08AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014), and was not extended.
Shire Successfully Completes Tender Offer for ViroPharma
PR Newswire - Fri Jan 24, 6:51AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014), and was not extended.
Shire Sells Dermagraft - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:55PM CST
Shire entered into a definitive agreement with Organogenesis Inc. to sell Dermagraft.
Shire Quickly Pulls Off Dermagraft
at The Street - Fri Jan 17, 8:37AM CST
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.
Tractor Supply Set to Join the S&P 500; Align Technology to Join MidCap 400; Roadrunner Transportation and Boise Cascade to Join S&P SmallCap 600
PR Newswire - Thu Jan 16, 4:50PM CST
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective after the close of trading on Thursday, January 23:
Small-Cap Growth Stocks: A Long-Term Winning Investment
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jan 16, 4:15PM CST
Follow @SelenaMaranjian // full story)
(0)
(0)Viropharma Inc. (VPHM) Stock Research Links
Scroll down for more posts ▼